A conditionally replication-defective cytomegalovirus vaccine elicits potent and diverse functional monoclonal antibodies in a phase I clinical trial

Abstract A conditionally replication-defective human cytomegalovirus (HCMV) vaccine, V160, was shown to be safe and immunogenic in a two-part, double-blind, randomized, placebo-controlled phase I clinical trial (NCT01986010). However, the specificities and functional properties of V160-elicited anti...

Cijeli opis

Bibliografski detalji

Glavni autori:	Leike Li, Daniel C. Freed, Yaping Liu, Fengsheng Li, Diane F. Barrett, Wei Xiong, Xiaohua Ye, Stuart P. Adler, Richard E. Rupp, Dai Wang, Ningyan Zhang, Tong-Ming Fu, Zhiqiang An
Format:	Artigo
Jezik:	Inglês
Izdano:	Nature Portfolio 2021-06-01
Serija:	npj Vaccines
Online pristup:	https://doi.org/10.1038/s41541-021-00342-3
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!